Equity research analysts expect Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Get Rating) to post ($0.24) earnings per share (EPS) for the current quarter, Zacks reports InvestmentResearch. Four analysts made Xeris Biopharma earnings estimates, with estimates ranging from ($0.27) to ($0.22). Xeris Biopharma reported earnings per share of ($0.30) in the same quarter last year, which would indicate a positive growth rate of 20% year over year. The company is expected to release its next quarterly results on Monday, January 1.
On average, analysts expect Xeris Biopharma to report annual earnings of ($0.78) per share for the current year, with EPS estimates ranging from ($0.87) to ($0. $70). For the next fiscal year, analysts expect the company to post earnings of ($0.42) per share, with EPS estimates ranging from ($0.50) to ($0.38). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts who follow Xeris Biopharma.
Xeris Biopharma Inc (NASDAQ:XERS – Get Rating) last released its quarterly results on Thursday, March 10. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.21). Xeris Biopharma posted a negative return on equity of 305.33% and a negative net margin of 248.68%. The company posted revenue of $21.43 million in the quarter, compared to $20.72 million expected by analysts. In the same quarter a year earlier, the company posted ($0.41) earnings per share.
Several research analysts have recently published reports on the company. HC Wainwright reissued a “buy” rating and issued a price target of $6.00 (down from $8.00 previously) on Xeris Biopharma shares in a Friday, March 11 research note. Mizuho lowered its price target on Xeris Biopharma from $8.00 to $6.00 and set a “buy” rating on the stock in a Wednesday, March 16 research report. Zacks Investment Research upgraded Xeris Biopharma from a “hold” rating to a “sell” rating in a Thursday, Jan. 20, research report. Finally, SVB Leerink lowered its price target on Xeris Biopharma from $8.00 to $6.00 and set an “outperform” rating on the stock in a Wednesday, February 16 research report.
Separately, insider Steven Prestrelski sold 11,228 shares of the company in a trade on Tuesday, February 22. The stock was sold at an average price of $2.42, for a total value of $27,171.76. The sale was disclosed in a filing with the Securities & Exchange Commission, available on the SEC’s website. 4.01% of the shares are held by insiders of the company.
A number of hedge funds have recently changed their stock holdings. Stonepine Capital Management LLC purchased a new stock position in Xeris Biopharma during Q4, valued at approximately $16,573,000. FMR LLC increased its stake in Xeris Biopharma shares by 29.9% during the 1st quarter. FMR LLC now owns 2,963,018 shares of the company valued at $29,749,000 after purchasing an additional 682,050 shares in the last quarter. BlackRock Inc. increased its stake in shares of Xeris Biopharma by 17.7% during the 4th quarter. BlackRock Inc. now owns 1,795,513 shares of the company valued at $5,261,000 after purchasing an additional 269,705 shares in the last quarter. Geode Capital Management LLC increased its stake in the shares of Xeris Biopharma by 42.7% during the 4th quarter. Geode Capital Management LLC now owns 1,005,000 shares of the company valued at $2,944,000 after purchasing an additional 300,830 shares in the last quarter. Finally, Renaissance Technologies LLC increased its stake in Xeris Biopharma shares by 519.8% during the 4th quarter. Renaissance Technologies LLC now owns 880,194 shares of the company valued at $2,579,000 after purchasing an additional 738,182 shares in the last quarter. Institutional investors hold 46.52% of the company’s shares.
NASDAQ: XERS traded down $0.04 in Friday’s midday session, hitting $2.33. The stock had a trading volume of 1,485,209 shares. Xeris Biopharma has a 1-year minimum of $1.77 and a 1-year maximum of $4.98. The stock has a 50-day moving average of $2.53 and a 200-day moving average of $2.35. The company has a quick ratio of 1.57, a current ratio of 1.80 and a leverage ratio of 0.92.
About Xeris Biopharma (Get an evaluation)
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for endocrinology, neurology and gastroenterology patient populations. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycaemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proven to treat endogenous hypercortisolemia in adult patients with Cushing’s syndrome.
Get a Free Copy of Zacks Research Report on Xeris Biopharma (XERS)
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
Get news and reviews for Xeris Biopharma Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Xeris Biopharma and related companies with MarketBeat.com’s free daily email newsletter.